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Sticking to PIP
 
2
 
he PIP
 
2
 
 phospholipid is required 
for calcium-dependent exocy-
tosis in at least some secretory cells, 
but its exact function has remained 
obscure. Now, Jihong Bai, Ward 
T
Syt has two modes of binding to PIP2.
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Tucker, and Edwin Chapman (University of Wisconsin, Madison, WI) find that 
PIP
 
2
 
 is a plasma membrane dock for synaptotagmin-1 (syt), a transmembrane 
protein localized in secretory vesicle membranes, when calcium is absent. This 
dock may ensure speedy and directed fusion in response to calcium influx.
The syt dock has two calcium-binding domains in its cytoplasmic region, 
called C
 
2
 
A and C
 
2
 
B. “What we discovered is that there are two modes of binding 
to PIP
 
2
 
 mediated by the C
 
2
 
B domain of syt,” says Chapman. In the absence 
of calcium, syt binds PIP
 
2
 
 weakly, lying on its side so that C
 
2
 
B contacts the 
PIP
 
2
 
 head group. Once the C
 
2
 
A and C
 
2
 
B domains bind to calcium, however, 
the protein flips over to allow the opposite face of C
 
2
 
B to bind to PIP
 
2
 
.
In this conformation, syt inserts membrane penetration prongs into the 
plasma membrane, potentially facilitating fusion with the secretory vesicle 
membrane and accelerating exocytosis. Thus, when calcium enters the cell, 
syt is already poised so that the first membrane C
 
2
 
B encounters is the plasma 
membrane. In other words, the syt-PIP
 
2
 
 interaction essentially steers the 
synaptic vesicle to the plasma membrane in preparation for exocytosis.
 
 
 
 
 
Reference:
 
Bai, J., et al. 2004. 
 
Nat. Struct. Mol. Biol.
 
 10.1038/nsmb709.
 
Parsing p53 activity
 
ertebrate p53 has many talents, including the ability to induce apoptosis 
and cell cycle arrest in response to DNA damage. At least one of these 
talents seems to be crucial for suppressing tumor formation, as mice that 
lack p53 develop early onset T-cell lymphomas and usually die young. 
New results from Geng Liu, Guillermina Lozano, and colleagues (M.D. 
Anderson Cancer Center, Houston, Texas) suggest that, for tumor initiation, 
delay trumps death.
The group made mice with a p53 point mutation that leaves the protein 
with the ability to delay cell cycle but not induce apoptosis. This mutation 
causes a much less severe phenotype than p53 deletions, with a long delay 
in tumor onset and only rare cases of lymphoma. They then showed that 
the decreased tumorigenesis is a result of the p53 cell cycle activity’s ability 
to maintain genome stability. Most of the tumor cells from p53 null mice 
were aneuploid, but those from mice with the point mutation remained 
diploid. The point mutation cells also had two centrosomes during division, 
whereas the null cells had multiple centrosomes that led to large chromo-
somal breaks and missegregations.
“If you look at the literature, it is almost dogma that the apoptosis function 
of p53 is the crucial activity for preventing tumorigenesis,” says Lozano. 
V
 
“Our data says that the cell cycle 
arrest function of p53 is as pivotal.” 
The tumors that do develop, however, 
tend to be aggressive, which supports 
the idea that apoptosis is critical for 
controlling tumor progression. 
 
 
 
Reference: Liu, G., et al. 2004. 
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Chromosome instability (left) 
is not a problem for cells with 
a p53 point mutation (right).
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RNAi-mediated 
DNA silencing
 
fter embracing RNAi’s ability to silence and 
degrade transcripts, biologists have eyed 
reports that RNAi is required for heterochromatin 
assembly with skepticism. With new results 
showing that siRNAs are essential for targeting a 
heterochromatin-associated protein complex to 
DNA, André Verdel, Danesh Moazed (Harvard 
Medical School, Boston, Massachusetts), Shiv 
Grewal (National Cancer Institute, Bethesda, 
Maryland), and colleagues think that skepticism 
is now unfounded. “It leaves no doubt that RNAi 
is very directly involved in heterochromatin 
formation,” says Moazed. 
A
siRNAs target RITS to heterochromatin.
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Previous work showed that deletion of factors 
required for RNAi disrupted heterochromatin 
formation in yeast, implying that RNAi was 
involved in transcriptional gene silencing. Now, 
the authors have purified an RNAi effector 
complex (RITS) that contains Ago1 (the 
homologue of the siRNA-associated protein 
Argonaute), a heterochromatin associated protein 
Chp1, a novel protein Tas3, and small siRNAs 
complementary to centromeric DNA repeats.
Mutations of Tas3 disrupt heterochromatin 
formation and block association of methylated 
histone-3 with DNA, a phenotype that resembles 
the previously described mutants of Ago1 and 
Chp1. Targeting the RITS complex to DNA 
requires siRNAs—in yeast strains lacking Dicer, 
the enzyme that produces siRNAs, the proteins 
associate but fail to find chromatin. RITS may 
recruit histone modifying enzymes to chromatin 
and initiate heterochromatin assembly. Although 
Verdel et al. expect these associations to be tran-
sient, they are working to detect them directly. 
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